Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies.

摘要: Repaglinide is a new carbamoylmethyl benzoic acid derivative that structurally related to meglitinide. In common with all active oral hypoglycaemic agents, it displays comparable U-shaped configuration. exerts its effects by binding site on the plasma membrane of beta-cells, thereby closing ATP-sensitive potassium channels. This causes depolarization beta-cell and opening voltage-sensitive calcium channels allowing influx extracellular ions. increase in intracellular calcium, turn, stimulates insulin release. The insulinotropic effect repaglinide not ionophoretic capacity. does cause release absence exogenous glucose, nor inhibit biosynthesis proinsulin. vivo administration an ester succinic potentiates secretory response concomitantly administered repaglinide. more rapid levels rats than either glibenclamide or glimepiride.